Cite
HARVARD Citation
Winer, E. et al. (2021). Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. Lancet oncology. 22 (4), pp. 499-511. [Online].